Paper32420566
Development of mucoadhesive cationic polypeptide micelles for sustained cabozantinib release and inhibition of corneal neovascularization.
Han H and 9 others. J Mater Chem B, 2020. Cited by 45 papers, by iCite.
Cite this record
ConductScience Library. Development of mucoadhesive cationic polypeptide micelles for sustained cabozantinib release and inhibition of corneal neovascularization. Papers, record 32420566. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32420566
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Development of mucoadhesive cationic polypeptide micelles for sustained cabozantinib release and inhibition of corneal neovascularization.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adhesives | Major topic |
| Angiogenesis Inhibitors | Major topic |
| Anilides | Major topic |
| Biocompatible Materials | Major topic |
| Corneal Neovascularization | Major topic |
| Peptides | Major topic |
| Pyridines | Major topic |
| Animals | |
| Cations | |
| Cell Proliferation | |
| Cells, Cultured | |
| Drug Liberation | |
| Humans | |
| Mice | |
| Micelles | |
| Particle Size | |
| Sodium Hydroxide | |
| Surface Properties |
Source PubMed
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 45 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41340913 | From design to Deployment: The innovative role of nanomicelles in targeted ophthalmic therapeutics. | Mater Today Bio | 2025 | https://conductscience.org/library/papers/41340913 | PubMed |
| 41121132 | Transforming corneal alkali burn treatment: unveiling mechanisms and pioneering therapies from bench to bedside. | J Transl Med | 2025 | https://conductscience.org/library/papers/41121132 | PubMed |
| 40454890 | Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape. | Small | 2025 | https://conductscience.org/library/papers/40454890 | PubMed |
| 40093887 | Recent advances and prospects of nanoparticle-based drug delivery for diabetic ocular complications. | Theranostics | 2025 | https://conductscience.org/library/papers/40093887 | PubMed |
| 39755928 | Progress in Nanotechnology for Treating Ocular Surface Chemical Injuries: Reflecting on Advances in Ophthalmology. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/39755928 | PubMed |
| 39367103 | Novel ophthalmic hyaluronic acid-hydrogel with curcumin nanoparticles for enhanced healing of ulcerative keratitis in rabbit model. | Sci Rep | 2024 | https://conductscience.org/library/papers/39367103 | PubMed |
| 39014353 | Preparation and in vivo and ex vivo studies of sirolimus nano-in-situ gel ophthalmic formulation. | J Nanobiotechnology | 2024 | https://conductscience.org/library/papers/39014353 | PubMed |
| 38406994 | Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management. | Adv Healthc Mater | 2024 | https://conductscience.org/library/papers/38406994 | PubMed |
| 38202631 | Exploring the Role of Lycium barbarum Polysaccharide in Corneal Injury Repair and Investigating the Relevant Mechanisms through In Vivo and In Vitro Experiments. | Molecules | 2023 | https://conductscience.org/library/papers/38202631 | PubMed |
| 37600322 | Recent development of polymer nanomicelles in the treatment of eye diseases. | Front Bioeng Biotechnol | 2023 | https://conductscience.org/library/papers/37600322 | PubMed |
| 37004870 | Targeted dexamethasone nano-prodrug for corneal neovascularization management. | Biomed J | 2024 | https://conductscience.org/library/papers/37004870 | PubMed |
| 36292932 | Design of Cyclic Peptide-Based Nanospheres and the Delivery of siRNA. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36292932 | PubMed |
| 36267540 | An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization. | Int J Nanomedicine | 2022 | https://conductscience.org/library/papers/36267540 | PubMed |
| 35600640 | Ferrostatin-1-loaded liposome for treatment of corneal alkali burn via targeting ferroptosis. | Bioeng Transl Med | 2022 | https://conductscience.org/library/papers/35600640 | PubMed |
| 35435328 | Anti-Oxidative and Anti-Inflammatory Micelles: Break the Dry Eye Vicious Cycle. | Adv Sci (Weinh) | 2022 | https://conductscience.org/library/papers/35435328 | PubMed |
| 35261643 | Emerging pro-drug and nano-drug strategies for gemcitabine-based cancer therapy. | Asian J Pharm Sci | 2022 | https://conductscience.org/library/papers/35261643 | PubMed |
| 35185587 | Tacrolimus Loaded Cationic Liposomes for Dry Eye Treatment. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35185587 | PubMed |
| 34950647 | Inhibition of Neovascularization and Inflammation in a Mouse Model of Corneal Alkali Burns Using Cationic Liposomal Tacrolimus. | Front Bioeng Biotechnol | 2021 | https://conductscience.org/library/papers/34950647 | PubMed |
| 34820575 | Drug-eluting intraocular lens with sustained bromfenac release for conquering posterior capsular opacification. | Bioact Mater | 2022 | https://conductscience.org/library/papers/34820575 | PubMed |
| 34765592 | Ocular Wnt/β-Catenin Pathway Inhibitor XAV939-Loaded Liposomes for Treating Alkali-Burned Corneal Wound and Neovascularization. | Front Bioeng Biotechnol | 2021 | https://conductscience.org/library/papers/34765592 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32420566
GET https://conductscience.org/api/papers/v1/32420566/cited_by?page=2